Currently viewing the tag: "Topotarget"
After a hectic day – its time for a little soulsearching. I have no shares in TopoTarget, but that’s just a coincidence, I might as well have had; but basically I am always a little wary with “one-trick-pony’s “- especially biotech-ponies –
Relying on just one product-line is dangerous, it’s 100% make/break … But after todays […]
This is TopoTarget at a glance, hopefully this will provide you with an overview of one of the most exiting Biotech companies in Denmark.
Apart from telling you a bit about the investment-opportunity, I (investor89) will also make a laymans explanation of some the abbreviations you will encounter when studying TopoTarget
TopoTarget themselves describe the […]
Practically every day these weeks, new surveys and studies are being published about Belinostat. Today, a study regarding the effect of belinostat in International Journal of Gynecological Cancer titled:
Conclusions: Belinostat, carboplatin, and paclitaxel combined was reasonably […]
By popular demand – we are including TopoTarget in the Medicoinvestor universe.. apparently important data is coming within 3 weeks.
We hope that loads of interesting analytic posts – (of quality and some substance 🙂 ) about TopoTarget will find their way to Medicoinvestor.
Druen and I have very limited knowledge regarding TopoTarget – […]
Ongoing debate
- James Rolitson on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Thomas Goldberg on Good Discussion on Bronte Capital’s long thesis on Herbalife
- Spekulant.dk on dashboard
- Muldyr on dashboard
- kasperlindvig on dashboard
